

CHAIR:

Alan F. List, MD
H. Lee Moffit Cancer Center
and Research Institute
Tampa, Florida

A Luncheon Symposium at the
6th International Congress on
Myeloproliferative Diseases and
Myelodysplastic Syndromes

UNTANGLING THE CONTROVERSY:

**IMPACT AND MANAGEMENT
OF IRON OVERLOAD in MDS**

NOVEMBER 3, 2011 - NEW YORK, NEW YORK

New York Marriott at the Brooklyn Bridge
Salon E-I

FACULTY:

Heather Leitch, MD, PhD, FRCP
Providence Hematology
Vancouver, Canada

Alan F. List, MD
H. Lee Moffit Cancer Center
& Research Institute
Tampa, Florida

Jerry L. Spivak, MD, FACP
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

David P. Steensma, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

SCIENTIFIC AGENDA:

- | | |
|----------|--|
| 11:15 am | Lunch |
| 11:35 am | Welcome and pre-activity ARS
<i>Alan F. List, MD</i> |
| 11:40 am | Putting the iron overload management guidelines into practice – patient selection, drug selection, and monitoring
<i>Jerry L. Spivak, MD, FACP</i> |
| 12:00 pm | Debate: Should iron overload be a focus of treatment in MDS patients?

Yes, the benefits of iron chelation outweigh the costs
<i>Heather Leitch, MD, PhD, FRCP</i>

No, MDS treatment should focus on reducing transfusion dependence and other goals
<i>David P. Steensma, MD</i> |
| 12:30 pm | Future management of iron overload in MDS – recent findings and ongoing trials
<i>Alan F. List, MD</i> |
| 12:50 pm | Panel discussion and Q&A |
| 1:00 pm | Concluding remarks and post-activity ARS
<i>Alan F. List, MD</i> |
| 1:05 pm | Adjourn |